Tanja Kuehbacher

Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial

Séverine Vermeire, Stefan Schreiber, Robert Petryka et al. · The Lancet · 2016 · 439 citations

Pharmacy, Clinical Sciences, Pharmacotherapy +13

Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study

Jan Menne, Martin Nitschke, Robert Stingele et al. · BMJ · 2012 · 306 citations · Full text

Medicine, Infectious Diseases, Pharmacotherapy +9

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial

Bruce E. Sands, Peter M. Irving, Timothy Hoops et al. · The Lancet · 2022 · 297 citations · Full text

Medicine, Clinical Sciences, Immunology +17

Intestinal TM7 bacterial phylogenies in active inflammatory bowel disease

Tanja Kuehbacher, Ateequr Rehman, Patricia Lepage et al. · Journal of Medical Microbiology · 2008 · 194 citations

Life Sciences, Microbiology, Medical Microbiology +16

Endoscopic ultrasound of the colon for the differentiation of Crohn's disease and ulcerative colitis in comparison with healthy controls

Mark Ellrichmann, Shantiswaroop Dhar, Susanna Nikolaus et al. · Alimentary Pharmacology & Therapeutics · 2014 · 79 citations

Medicine, Pathology, Gastroenterology +16